Company Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.
The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis.
Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Country | United States |
| Founded | 1999 |
| IPO Date | Aug 11, 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 91 |
| CEO | A. Kazimi |
Contact Details
Address: 1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203 United States | |
| Phone | 615 255 0068 |
| Website | cumberlandpharma.com |
Stock Details
| Ticker Symbol | CPIX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001087294 |
| CUSIP Number | 230770109 |
| ISIN Number | US2307701092 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| A. J. Kazimi MBA | Founder, Chairman, President and Chief Executive Officer |
| John Michael Hamm C.M.A. | Vice President and Chief Financial Officer |
| James Lowrance Herman | Vice President of Trade and Distribution and Chief Compliance Officer |
| ChristopherT. Bitterman | Vice President of Sales and Marketing |
| Todd M. Anthony | Vice President of Organizational Development |
| Jean W. Marstiller | Senior Vice President of Administrative Services and Corporate Secretary |
| Adam S. Mostafa | Managing Director of Banking and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 9, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 24, 2025 | SCHEDULE 13G/A | Filing |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 18, 2025 | ARS | Filing |
| Mar 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |